Status:
ACTIVE_NOT_RECRUITING
Autoantibodies Against Type I Interferon in Patients Affected With Ph-negative Myeloproliferative Neoplasms (MPN-IFN Study)
Lead Sponsor:
Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions:
Myeloproliferative Disease
COVID - 19
Eligibility:
All Genders
18+ years
Brief Summary
The classic Ph-negative myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic disorders caused by a dysregulated JAK/STAT signal transduction because of acquired somatic mutations of ...
Eligibility Criteria
Inclusion
- A diagnosis of PV, ET, prePMF, overt PMF or MPN-U according to 2016 WHO criteria
- Characterization of the MPN driver mutation performed at any moment before enrolment
- A peripheral blood (PB) sample collected at the enrolment visit suitable for plasma extraction and functional evaluation of anti-cytokine auto-Abs
Exclusion
- None
Key Trial Info
Start Date :
May 6 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2030
Estimated Enrollment :
219 Patients enrolled
Trial Details
Trial ID
NCT07204366
Start Date
May 6 2022
End Date
December 31 2030
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, Italy, 27100